MASTERINVEST Kapitalanlage GmbH Decreases Holdings in Gilead Sciences, Inc. $GILD

MASTERINVEST Kapitalanlage GmbH reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 21,165 shares of the biopharmaceutical company’s stock after selling 6,698 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in Gilead Sciences were worth $2,349,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in GILD. Rothschild Investment LLC boosted its stake in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 84 shares during the last quarter. Ignite Planners LLC increased its stake in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the last quarter. Archer Investment Corp raised its holdings in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. Binnacle Investments Inc raised its holdings in shares of Gilead Sciences by 14.3% in the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Finally, EPG Wealth Management LLC lifted its stake in Gilead Sciences by 2.0% in the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after purchasing an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD opened at $121.10 on Friday. The stock’s 50-day simple moving average is $123.27 and its two-hundred day simple moving average is $117.51. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a market capitalization of $150.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the insider owned 106,221 shares of the company’s stock, valued at $12,958,962. The trade was a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares in the company, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 136,257 shares of company stock worth $16,855,192. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on GILD shares. Rothschild & Co Redburn raised their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Scotiabank began coverage on Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. HSBC boosted their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Needham & Company LLC upped their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, BMO Capital Markets set a $135.00 price target on shares of Gilead Sciences in a research note on Tuesday, November 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $133.20.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.